Juniper Pharmaceuticals announces 4.5-year extension through 2024 of Crinone supply agreement with Merck KGaA, Darmstadt, Germany.
Juniper Pharmaceuticals a diversified healthcare company focused on women’s health, announced the extension of its supply agreement for Crinone (progesterone gel) with an affiliate of Merck KGaA, Darmstadt, Germany.
The amended agreement extends the supply term an additional 4.5 years and at least through to December 31, 2024. The current term was due to expire in May 2020.
Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the United States, where Crinone is marketed by Allergan plc.
“Our longstanding collaboration with Merck KGaA, Darmstadt, Germany to supply Crinone progesterone gel for sale outside of the U.S. remains an extremely important core business for us. We anticipate approximately 20 percent growth in 2017, and expect continued long-term growth throughout the extension period,” said Alicia Secor, Juniper’s president and CEO.
Under the terms of the amended license and supply agreement, Juniper will remain the supplier of Crinone to Merck KGaA, Darmstadt, Germany and will continue to sell Crinone to Merck KGaA, Darmstadt, Germany for the more than 90 countries outside of the U.S. where Crinone is sold.
The agreement also sets from July 1, 2020, a volume tiered, fixed price per unit with minimum annual volume guarantees. In addition, Juniper has committed to increase the capacity of its supply chain in line with the projected growth of the product.
Juniper previously reported that Crinone product revenues increased 19 percent year-over-year in the third quarter of 2017. The company recently announced that it expects continued strong double-digit revenue growth for its core business, Crinone and JPS, in 2018.
(Source: Juniper Pharmaceuticals, Inc.)